Johnson & Johnson

As of June 30, 2026, Johnson & Johnson carries a market capitalization of 504.74T, placing it among publicly traded companies globally. Its enterprise value stands at 530.95T, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Johnson & Johnson's next confirmed earnings release is scheduled for January 26, 2027.

As of June 30, 2026, Johnson & Johnson has 2.41B shares outstanding.

As of June 30, 2026, Johnson & Johnson trades at a trailing price-to-earnings ratio of 25.88. The price-to-sales ratio is 5.56, and the price-to-book ratio stands at 6.41.

As of June 30, 2026, Johnson & Johnson trades at an EV/EBITDA multiple of 17.64 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 5.85 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 23.17 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. Johnson & Johnson trades at an EV/FCF ratio of 24.83, comparing the total takeover cost of the business to the cash it actually generates for all capital providers. These enterprise value multiples are built on an enterprise value of 530.95T versus a market cap of 504.74T, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, Johnson & Johnson maintains a current ratio of 1.09, meaning it holds 1.1x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 57.71, indicating elevated leverage, while an interest coverage ratio of 32.09 demonstrates strong ability to service its debt obligations.

Over the twelve months ended June 30, 2026, Johnson & Johnson posted a return on equity (ROE) of 25.74, showing how much profit the company earns on every dollar of shareholder capital. Return on invested capital (ROIC) comes in at 15.55 - the clearest signal of whether the business earns more on its capital than that capital costs, and the core measure of a durable competitive advantage. Return on assets (ROA) stands at 10.67, measuring how efficiently the asset base is converted into earnings. Return on capital employed (ROCE) is 16.63, useful for judging operating efficiency across full business cycles. The company generates approximately 645.74M in revenue per employee across its workforce of 140,550.00, a quick read on workforce productivity versus industry peers. Inventory turnover of 2.20 indicates how many times Johnson & Johnson sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended June 30, 2026, Johnson & Johnson recorded 3.85T in income tax expense. That works out to an effective tax rate of 16.51, which can sit above or below the statutory corporate tax rate depending on foreign earnings mix, tax credits, and one-off items. Taxes are levied on pretax income of 23.35T, leaving 19.50T in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.

As of the close on September 8, 2026, Johnson & Johnson's stock has gained approximately 44.44% over the past 52 weeks. The 50-day moving average sits at 170,474.02, while the 200-day moving average is 151,518.38.

Over the twelve months ended June 30, 2026, Johnson & Johnson generated 90.76T in revenue and converted that into 19.50T in net income, yielding earnings per share of 7,996.26. EBITDA reached 30.10T, while operating income came in at 24.33T.

As of June 30, 2026, Johnson & Johnson holds 19.24T in cash and equivalents against 45.45T in total debt, resulting in a net debt position of 26.52T. Total book value stands at 78.75T, with working capital of 4.52T providing operational flexibility.

Johnson & Johnson produced 25.59T in operating cash flow over the twelve months ended June 30, 2026. After subtracting -4.99T in capital expenditures, free cash flow totaled 20.60T - equivalent to 8,555.84 per share.

Over the twelve months ended June 30, 2026, Johnson & Johnson posted a gross margin of 67.91, reflecting its pricing power and cost economics. The operating margin of 26.81 and net profit margin of 21.48 provide insight into operational efficiency.

Over the twelve months ended June 30, 2026, Johnson & Johnson paid dividends of 4,857.99 per share. The dividend payout ratio of 59.99 indicates the proportion of earnings distributed to shareholders, a key gauge of how sustainable the dividend is and how much room remains for future dividend growth. Free cash flow yield stands at 4.03, showing how much cash the business generates relative to its market value - dividends covered by free cash flow are generally more durable than those funded by debt. Total shareholder yield reaches 3.40, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to Johnson & Johnson shareholders.

Johnson & Johnson's most recent stock split took place on June 13, 2001 with a 1:2 split ratio.